Research Reports | Market Assessment
June 2018

Atrial Fibrillation | Treatment Algorithms | Claims Data Analysis | US | 2018

For the estimated 5 million people in the United States with atrial fibrillation (AF), several treatment approaches can be used, each of which has a wide range of pharmacological options. Guidelines from the American Heart Association, American College of Cardiology Foundation, and Heart Rhythm Society recommend the implementation of rate control therapy to control heart rate and rhythm control treatment to establish a normal sinus rhythm for appropriate patients. The use of rate and/or rhythm control is often accompanied by antithrombotic therapies to reduce the risk of stroke in at-risk patients. This report provides quantitative analysis of treatment patterns, patient share by line of therapy, progression between lines, duration of treatment on each line, and use of concomitant treatment.

Questions Answered:

  • What patient shares do key therapies and drug classes command by line of therapy in newly diagnosed AF patients?
  • What proportion of AF patients receive drug treatment within 720 days of initial diagnosis? How many progress to second or third lines of treatment within 720 days?
  • How have the direct FXa inhibitors been integrated into the AF treatment algorithm, and to what extent have they displaced warfarin?
  • Does Eliquis or Xarelto command a greater patient share, and uptake of which drug is growing at the fastest pace?
  • What are the product-level compliance and persistency rates among drug-treated AFpatients

Product Description

Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand use across different lines of therapy using real-world patient-level claims data so that clients can accurately assess their source of business and quantify areas of opportunity for increasing their brand share.

Markets covered: United States

Real-world data: Longitudinal patient-level claims data analysis

Key companies: Bayer, Bristol-Myers Squibb, Pfizer, Daiichi Sankyo, Boehringer Ingelheim

Key drugs: Xarelto, Eliquis, Savaysa, Pradaxa, Warfarin

Key analysis provided:

  • Brand use across longitudinal patient sample.
  • Newly diagnosed patient analysis.
  • Treatment initiation and progression.
  • Line of therapy analysis.
  • Combination therapy analysis.
  • Source of business for recently treated patients.
  • Persistency and compliance analysis.
  • Product-level patient flowcharts.
Login to access report
Back to all Market Assessment reports
Login to access report

launch Related Market Assessment Reports